High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary carcinomas. Triple-negative tumors account for 15% of all breast cancers and fre...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rottenberg, Sven, Jaspers, Janneke E., Kersbergen, Ariena, van der Burg, Eline, Nygren, Anders O. H., Zander, Serge A. L., Derksen, Patrick W. B., de Bruin, Michiel, Zevenhoven, John, Lau, Alan, Boulter, Robert, Cranston, Aaron, O'Connor, Mark J., Martin, Niall M. B., Borst, Piet, Jonkers, Jos
Médium: Artigo
Jazyk:Inglês
Vydáno: National Academy of Sciences 2008
Témata:
Biological Sciences
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2579381/
https://ncbi.nlm.nih.gov/pubmed/18971340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0806092105
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky